CELECOXIB

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-21-D-0130

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Hauppauge, New York, UNITED STATES

SourceSAM
Documents2
This procurement notice announces the award of a national contract for the supply of Celecoxib capsules, intended to support the Defense Logistics Agency (DLA) Troop Support’s pharmaceutical requirements. The contract falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under Product Service Code 6505, indicating its focus on drugs and biologicals. The place of performance for this contract is Hauppauge, New York, USA. The primary objective of this procurement is to ensure a reliable and consistent supply of Celecoxib capsules for DLA Troop Support, which is responsible for providing medical and pharmaceutical products to military personnel and associated federal entities. The scope of the contract encompasses the manufacturing and delivery of Celecoxib capsules that meet all applicable federal quality and safety standards, supporting the health and readiness of the armed forces. Key requirements for this contract include the capability to manufacture pharmaceutical-grade Celecoxib capsules in compliance with all regulatory guidelines, as well as the logistical capacity to deliver these products to designated DLA facilities as needed. Contractors are expected to maintain rigorous quality assurance processes and adhere to the specifications outlined by DLA Troop Support. The contracting entity for this award is DLA Troop Support, a federal office located in the United States, with primary contacts Ryan Ferry ([email protected], 215-737-3182) and Jason Wray ([email protected], 215-737-0614) available for further inquiries. The notice remains active as of its posting date, May 26, 2022, and additional details, including attachments, can be accessed via the official SAM.gov opportunity listing. This award notice is relevant for contractors with established pharmaceutical manufacturing capabilities, particularly those experienced in producing nonsteroidal anti-inflammatory drugs (NSAIDs) like Celecoxib. The opportunity aligns with organizations that can demonstrate compliance with federal procurement standards and have the infrastructure to support national-level supply contracts. No set-aside requirements or special considerations are specified in the notice. For further information and to review associated documents, interested parties are encouraged to visit the official notice at: https://sam.gov/opp/e58a05ab2a1f4d7880044782beb8d1aa/view.